Skip to content

A prospective, randomized, blind, controlled multicenter clinical study comparing the effectiveness of preventive ventricular arrhythmia ablation on the prognosis after left ventricular assist device (LVAD) surgery.

A prospective, randomized, blind, controlled multicenter clinical study comparing the effectiveness of preventive ventricular arrhythmia ablation on the prognosis after left ventricular assist device (LVAD) surgery.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117097
Enrollment
Unknown
Registered
2026-01-20
Start date
2026-01-20
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CHF(congestive heart-failure)

Interventions

preventive ablation group:for patients undergoing LVAD surgery while also undergoing prophylactic ablation of ventricular arrhythmias at the same time
the control group without any treatmen:no intervention measures

Sponsors

The First Affilitaed Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1.voluntary and with the provision of an informed consent form 2.males or females aged 18 years or older 3.all patients with acute and critical or chronic advanced heart failure who have failed to respond to standardized oral medication and are scheduled to undergo artificial heart implantation surgery

Exclusion criteria

Exclusion criteria: 1.The left ventricular assist system is prohibited for patients who cannot tolerate anticoagulant therapy or who are allergic to anticoagulant treatment. 2.Doctors with sufficient experience will make a comprehensive judgment based on the patient's physical condition, body surface area, and the anatomical-related conditions of the planned implantation site, and determine those who are not suitable for the implantation procedure. 3.Pregnant women. 4.Systemic active infection. 5.Patients in a state of brain death. 6.Irreversible severe liver or kidney dysfunction. 7.Having a history of severe chronic obstructive pulmonary disease (COPD) or restrictive lung disease. 8.primary pulmonary hypertension. 9.Having a confirmed and untreated history of abdominal or thoracic aortic aneurysm with a diameter greater than 5 cm. 10.Patients with severe atherosclerotic plaques in the aorta. 11.Having mental disorders/impairments, irreversible cognitive dysfunction, or social-psychological problems, which makes it possible for the patient to fail to comply with the application management regulations of the implanted left ventricular assist device. 12.Preoperative conditions included end-stage organ failure, such as renal failure (requiring hemodialysis), liver failure, respiratory failure; and concurrent malignant tumors or any severe accompanying diseases with an expected lifespan of less than 3 years.

Design outcomes

Primary

MeasureTime frame
persistent ventricular tachycardia / ventricular fibrillation;all-cause mortality;mechanical thrombus;right heart failure;

Secondary

MeasureTime frame
all-cause mortality;mechanical thrombus;stroke;Hospitalization or emergency visit due to heart failure;heart transplantation;

Countries

China

Contacts

Public ContactChengxin Zhang

The First Affilitaed Hospital of Anhui Medical University

zhangchengxin@ahmu.edu.cn+86 138 5603 2992

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026